Elevated aldehyde dehydrogenase (ALDH) activity correlates with greater drug resistance and metastatic potential across multiple cancer types and the ALDH superfamily—particularly ALDH1A3—plays a key role in driving malignant progression and gemcitabine resistance in patients with advanced CCA [153]. Here, LDHA is linked to cholangiocarcinoma.